Long Shortz with Argenica Therapeutics: Unpacking the Phase 2 trial results

Argenica Therapeutics (ASX:AGN) managing director and CEO Dr Liz Dallimore joins host Fraser Palamara on Stockhead TV following the topline Phase 2 trial results of the company’s ARG-007 neuroprotective peptide drug.

ARG-007 is designed to reduce the impacts on victims of acute ischemic stroke, with the latest test results providing what goals have been achieved, and what AGN’s next moves will be.

Tune in to hear all the details.

This video was developed in collaboration with Argenica Therapeutics, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.